News
Breaking Down Jazz Pharmaceuticals: 15 Analysts Share Their Views
10 Apr 24
Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Jazz Pharmaceuticals, Maintains $180 Price Target
10 Apr 24
News, Price Target, Reiteration, Analyst Ratings
How To Make Your Cannabis Business More Attractive For Investors In 2024: Advice On Financial Health & Innovation
25 Mar 24
Cannabis, News, Events
Cantor Fitzgerald Reiterates Overweight on Jazz Pharmaceuticals, Maintains $180 Price Target
22 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Truist Securities Reiterates Buy on Jazz Pharmaceuticals, Maintains $200 Price Target
20 Mar 24
News, Price Target, Reiteration, Analyst Ratings
The Analyst Landscape: 12 Takes On Jazz Pharmaceuticals
20 Mar 24
Analyst Ratings
Piper Sandler Reiterates Overweight on Jazz Pharmaceuticals, Raises Price Target to $188
20 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Piper Sandler Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $188
20 Mar 24
News, Price Target, Analyst Ratings
Stifel Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $230
15 Mar 24
News, Price Target, Analyst Ratings
HC Wainwright & Co. Maintains Buy Rating for Jazz Pharmaceuticals: Here's What You Need To Know
14 Mar 24
Analyst Ratings
HC Wainwright & Co. Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target to $200
14 Mar 24
News, Price Target, Analyst Ratings
Time Is Still The Enemy, Says Mom Who Moved Mountains For Her Epileptic Daughter & Still Advocates For Millions Of CBD Users
12 Mar 24
Cannabis, News, Exclusives, Interview
Avadel Pharmaceuticals Issues Statement On Patent Litigation; Statement In Response To Jury Ruling In Patent Suit Brought By Jazz Pharmaceuticals Inc. Regarding LUMRYZ
4 Mar 24
News, Legal
Cantor Fitzgerald Reiterates Overweight on Jazz Pharmaceuticals, Maintains $180 Price Target
29 Feb 24
News, Price Target, Reiteration, Analyst Ratings
RBC Capital Reiterates Outperform on Jazz Pharmaceuticals, Maintains $195 Price Target
29 Feb 24
News, Price Target, Reiteration, Analyst Ratings
JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $170
29 Feb 24
News, Price Target, Analyst Ratings
Demystifying Jazz Pharmaceuticals: Insights From 4 Analyst Reviews
29 Feb 24
Analyst Ratings
Needham Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target to $220
29 Feb 24
News, Price Target, Analyst Ratings
Earnings Scheduled For February 28, 2024
28 Feb 24
Earnings
Jazz Pharma Taps Philip Johnson as CFO Effective March 1, 2024 Taking Over from Renée Galá
21 Feb 24
News, Management
Press releases
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
17 Apr 24
Press Releases
Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting
10 Apr 24
Press Releases
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer
2 Apr 24
Press Releases
Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024
12 Mar 24
Press Releases
Agrify Corp Stock Presents Compelling Opportunity As Deal Flow Intensifies ($AGFY)
7 Mar 24
News, Press Releases
Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors
27 Feb 24
Press Releases
Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer
21 Feb 24
Press Releases
Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences
20 Feb 24
Press Releases
Jazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial Results on February 28, 2024
14 Feb 24
Press Releases
Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program
7 Feb 24
News, Contracts, Press Releases